[Immunocompetence and immunotherapy of patients with cancer of the kidney and bladder].
作者信息
Mokhort V A, Grigorovich N A, Strotskiĭ A V, Mavrichev A S
出版信息
Urol Nefrol (Mosk). 1986 Jan-Feb(1):66-74.
PMID:3513423
Abstract
摘要
相似文献
1
[Immunocompetence and immunotherapy of patients with cancer of the kidney and bladder].
Urol Nefrol (Mosk). 1986 Jan-Feb(1):66-74.
2
Lymphocyte-mediated cytotoxicity in patients with renal and transitional cell carcinoma receiving BCG.
Natl Cancer Inst Monogr. 1978 Dec(49):343-5.
3
Immunology of bladder cancer.
Minn Med. 1980 Mar;63(3):173-4.
4
5
BCG immunotherapy of bladder cancer: 20 years on.
Lancet. 1999 May 15;353(9165):1689-94. doi: 10.1016/S0140-6736(98)07422-4.
6
[Immunodiagnosis and immunotherapy of bladder tumors].
Urol Nefrol (Mosk). 1984 Jan-Feb(1):69-72.
7
Effect of BCG immunotherapy on cell-mediated cytotoxicity in bladder cancer patients following surgical treatment.
Tumori. 1981 May-Jun;67(3):177-82. doi: 10.1177/030089168106700303.
8
[Zeta chain level of T and NK cells in patients with renal-cell carcinoma and bladder cancer and its clinical significance].
Zhonghua Zhong Liu Za Zhi. 2004 Mar;26(3):158-60.
9
Bacillus Calmette-Guérin-pulsed dendritic cells stimulate natural killer T cells and gammadeltaT cells.
Int J Urol. 2007 Jun;14(6):532-8; discussion 538. doi: 10.1111/j.1442-2042.2006.01697.x.
10
CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
J Immunother. 2008 Jan;31(1):34-42. doi: 10.1097/CJI.0b013e3181587d29.
Zotero 插件